Cigna's Evernorth unit will participate in a new federal effort to expand access to fertility treatments.
President Donald Trump announced last week that EMD Serono has agreed to offer U.S. consumers a big discount when the consumers buy Gonal-F, a drug used by women undergoing in vitro fertilization, through a new TrumpRx.gov public pharmacy website.
CVS said its pharmacies would support the program by acting as pickup points for Gonal-F orders and providing advice.
Cigna has described itself as "a pharmacy partner to TrumpRx" in an announcement posted on the front page of its main corporate website.
Two Evernorth fertility medication pharmacies, Freedom Fertility and VFP Pharmacy Group, will support the fertility care access program by offering Gonal-F and other EMD Serono fertility treatments, such as Cetrotide, and Ovidrel, "at the lowest cash price available today," the company said in the announcement.
Cigna suggested that the program could affect employer plans.
"We partner with a wide range of employers to build fertility benefits, covering millions of Americans," Brian Evanko, president and chief operating officer of the Cigna Group, said in a comment about the new effort. "We hope the new initiatives announced by President Trump will serve as a gateway to expand affordable IVF access to all Americans — either through their employer plan or through TrumpRx."
What it means: Evanko thinks the TrumpRx fertility drug access effort could end up increasing employer plan participants' access to fertility drugs.
TrumpRx.gov details: Cigna said it expects TrumpRx.gov to start operation in January 2026.
Cigna's effort: Cigna noted that its fertility pharmacies have been helping people with fertility care for 30 years and offer round-the-clock access to pharmacists with fertility expertise.
The program also offers injection trainings, and it notes that it has gained expertise by offering comprehensive fertility benefits to its own employees.
The backdrop: CVS, the parent of Aetna, and Cigna, the parent of Evernorth and Express Scripts, have announced TrumpRx.gov fertility drug access participation as insurers have started the annual enrollment period for Medicare Advantage plans and Medicare Part D prescription drug plans for 2026, and as health insurers are moving into the open enrollment period for Affordable Care Act public exchange plan coverage, which is set to begin Nov. 1.
Health insurers' conversations with federal officials about TrumpRx.gov could have difficult-to-predict effects on the enrollment period efforts and other federal operations that intersect with commercial health insurance and employer health plans.
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.